Literature DB >> 11961060

Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat.

Lilian Y Li1, Gordon L Amidon, Jae Seung Kim, Tycho Heimbach, Filippos Kesisoglou, John T Topliss, David Fleisher.   

Abstract

The purpose of this study was to investigate transport and metabolism contributions to low indinavir permeability in rat ileum and enhanced drug permeability in the jejunum. Permeability models utilized included single pass in situ rat intestinal perfusion and rat intestinal tissue mounted in Ussing chambers. Intestinal metabolism was measured by fractional appearance of metabolite (F(met)), determined as the percentage of the predominant metabolite M6 over luminal loss of indinavir in the perfusion model. Among the results, indinavir exhibited bidirectional transport across rat ileum. Verapamil and cyclosporin A inhibited net flux by 37 and 38%, respectively. Intestinal metabolism of indinavir was most significant in upper jejunum (F(met) = 65.78 +/- 19.02%), decreasing in midjejunum (F(met) = 31.58 +/- 5.63%). M6 was not detectable in ileum or colon. Western blot analysis of rat intestinal mucosal tissue samples confirmed that the axial expression of CYP3A was consistent with the regional pattern of formation of M6. Intestinal metabolism was saturable and could be inhibited by the CYP3A inhibitor, ketoconazole. A low luminal concentration of indinavir (1 microM) was associated with high F(met) (87.90 +/- 14.30%), whereas a high luminal concentration of indinavir (50 microM) was associated with low F(met) (35.84 +/- 11.59%). In the presence of ketoconazole, both F(met) and permeability of indinavir were reduced in the jejunum. These results suggest that 1) intracellular metabolism of indinavir enhances apical uptake of indinavir in the rat jejunum as a function of the increased concentration gradient generated across the epithelial cell membrane and 2) the efflux transporter P-glycoprotein limits apical uptake of indinavir in the ileum, resulting in low apparent permeability.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2002        PMID: 11961060     DOI: 10.1124/jpet.301.2.586

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts.

Authors:  K Sandy Pang; Michael Weiss; Panos Macheras
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

2.  Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice.

Authors:  Manuela Pereira de Oliveira; Emmanuel Garcion; Nicolas Venisse; Jean-Pierre Benoit; William Couet; Jean-Christophe Olivier
Journal:  Pharm Res       Date:  2005-11       Impact factor: 4.200

3.  Regional-dependent intestinal permeability and BCS classification: elucidation of pH-related complexity in rats using pseudoephedrine.

Authors:  Moran Fairstein; Rotem Swissa; Arik Dahan
Journal:  AAPS J       Date:  2013-02-26       Impact factor: 4.009

4.  Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate.

Authors:  Sanna Tolle-Sander; Jarkko Rautio; Steve Wring; Joseph W Polli; James E Polli
Journal:  Pharm Res       Date:  2003-05       Impact factor: 4.200

5.  Serine peptide phosphoester prodrugs of cyclic cidofovir: synthesis, transport, and antiviral activity.

Authors:  Ulrika Eriksson; Larryn W Peterson; Boris A Kashemirov; John M Hilfinger; John C Drach; Katherine Z Borysko; Julie M Breitenbach; Jae Seung Kim; Stefanie Mitchell; Paul Kijek; Charles E McKenna
Journal:  Mol Pharm       Date:  2008-05-16       Impact factor: 4.939

6.  Absorption rate limit considerations for oral phosphate prodrugs.

Authors:  Tycho Heimbach; Doo-Man Oh; Lilian Y Li; Markus Forsberg; Jouko Savolainen; Jukka Leppänen; Yasushi Matsunaga; Gordon Flynn; David Fleisher
Journal:  Pharm Res       Date:  2003-06       Impact factor: 4.200

7.  Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.

Authors:  Caroline Solas; Nicolas Simon; Marie-Pierre Drogoul; Sylvie Quaranta; Véronique Frixon-Marin; Véronique Bourgarel-Rey; Corinne Brunet; Jean-Albert Gastaut; Alain Durand; Bruno Lacarelle; Isabelle Poizot-Martin
Journal:  Br J Clin Pharmacol       Date:  2007-05-22       Impact factor: 4.335

Review 8.  Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models.

Authors:  Sheila Annie Peters; Christopher R Jones; Anna-Lena Ungell; Oliver J D Hatley
Journal:  Clin Pharmacokinet       Date:  2016-06       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.